Results

Total Results: 1,265 records

Showing results for "participants".

261. Evidence Summary: Hypertension in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/hypertension-in-adults-screening
     April 27, 2021 - Participants received their risk profile, risk-specific educational materials, and local community resource … Overall, participants represented a wide range of demographic and clinical characteristics, including … Overall, the participants represented a wide range of demographic and clinical characteristics. … First, it excluded accuracy studies in which 20% or more of participants were treated to approximate … Second, for confirmatory test accuracy (KQ3), studies were included that enrolled participants referred

262. Archived: Final Research Plan: Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Behavioral Counseling | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan17/healthy-diet-and-physical-activity-counseling-adults-with-high-risk-of-cvd-august-2014
     May 15, 2013 - Gait Sedentary behaviors Populations Adults At least 50% of participants … disease (other than hypertension or dyslipidemia) Persons with known CVD, such that >50% of participants … the USPSTF (which considers preventive services, not treatment and management), studies that enrolled participants

263. Screening for Eating Disorders in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/3M8fkpXfm-fkJZgKbhWcEM
     March 15, 2022 - Sample sizes ranged from 51 to 1541 participants (median, 341).1,27 Most studies assessed the SCOFF ( … No trials were found that enrolled participants who were screen-detected in primary care. … Study participants were either referred or recruited to treatment. … The major- ity of the trials enrolled mostly female participants and populations with binge eating disorder … Five trials (n = 208) evaluated vari- ous SSRIs in study participants with binge eating disorder and

264. Recommendation: Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication
     November 01, 2022 - harms of menopausal hormone therapy for this recommendation generally used the term “women” to describe participants … , although it is likely that these trials enrolled participants on the basis of sex, not gender identity … also been hypothesized that the benefits and harms of menopausal hormone therapy might differ based on participants … The WHI trials enrolled postmenopausal persons aged 50 to 79 years; the mean age of participants was … the benefits and harms of hormone therapy in postmenopausal persons might differ by the age of trial participants

265. Evidence for the Reaffirmation of the USPSTF Recommendaiton on Screening for High Blood Pressure (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/KSYrhQuAswGjTww_4sDFGZ
     December 01, 2007 - 7.6% Insomnia: 5.6% Anxiety: 5.6% Hypotension: 1% Syncope: 0.5% AEs were very common (about 89% of participants … In these 2 studies, participants with untreated hypertension were randomly allocated to differ- ent treatment … Julius and colleagues compared candesartan with pla- cebo in participants with systolic blood pressure … On average, participants were approximately 68 years of age, and 89% were white. … Participants were followed for 24 weeks; quality-of-life measures were collected at ran- domization,

266. Screening for Depression in Adults: A Summary of the Evidence (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/56vB_8UTTE_HjygLvJfYqM
     May 01, 2002 - than 75 or past history of depression) and met Screening for Depression in Adults 132 Absolute Participants … NR NR NR et al, 199018 Callahan et al, 199419 and 199621|| Percentage of 87% 88% –1% (–11% to 9%) participants … 6 months) Dowrick, 199520‡ NR NR NR Lewis et al, 199622‡ Percentage of 69% 74.5% –5 percentage participants … Participants who scored 16 or higher were given the Hamilton Depression Scale. … At 1 year of follow-up, 55% of depression management program participants and 72% of usual care recipients

267. Screening for Chronic Obstructive Pulmonary Disease: Evidence Report and Systematic Review for the USPSTF (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/BhnZRA--TRpXdg9_tYmZ_M
     April 05, 2016 - 3174 3983 1097 4592 All-Cause Mortality No. of studies 145 445,50,53,54 145 246,55 No. of participants … 3191 3732 1149 4076 Withdrawals No. of studies 145 445,50,51,54 245,51 146 No. of participants 1074 … Summary of Evidence Table Key Question Population No. of Studies No. of Participants Study Design Summary … Summary of Evidence Table (continued) Key Question Population No. of Studies No. of Participants Study … Summary of Evidence Table (continued) Key Question Population No. of Studies No. of Participants Study

268. Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/uM5P-6XpsqVfEC2axGnZaD
     November 16, 2020 - Smoking cessation rates were an average of 5.6% in participants receiving usual or minimal care and 9.5% … Participants in the control group may have also received some counseling or support, but it was less … Four of the stud- ies included participants who either wanted to stop smoking or were attending a stop … Study size ranged from 150 to 1124 participants. Reported trial findings were mixed. … One study reported that 26.9% of all study participants were using e-cigarettes at 1 year.77 Harms of

269. U.S. Preventive Services Task Force Issues Final Evidence Report for Screening for Cervical Cancer | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/announcements/us-preventive-services-task-force-issues-final-evidence-report-screening-cervical-cancer
     October 19, 2011 - They will not be able to respond to questions during the call, but will encourage participants to submit

270. Public Comment on Draft Recommendation: Screening for Cervical Cancer | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/announcements/public-comment-draft-recommendation-screening-cervical-cancer
     October 19, 2011 - They will not be able to respond to questions during the call, but will encourage participants to submit

271. Final Evidence Summary: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary51/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication
     April 08, 2014 - The fourth study was larger (554 participants), used a higher aspirin dose (150 mg), and enrolled women … Eleven trials (23,332 participants) reported on placental abruption (6 in women at increased preeclampsia … , n I 2 , % P Value RR (95% CI) Trials, n Participants, n I 2 , % P Value … [PMID: 1622907] 1, 2 <20 participants Marret S, Marchand L, Kaminski M, Larroque B, Arnaud … : 25.2 (5.7) Case patients: 62.0 Control participants: 66.0 NR No McParland et al, 1990

272. Archived: Final Evidence Summary: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary51/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication-september-2014
     April 08, 2014 - The fourth study was larger (554 participants), used a higher aspirin dose (150 mg), and enrolled women … Eleven trials (23,332 participants) reported on placental abruption (6 in women at increased preeclampsia … , n I 2 , % P Value RR (95% CI) Trials, n Participants, n I 2 , % P Value … [PMID: 1622907] 1, 2 <20 participants Marret S, Marchand L, Kaminski M, Larroque B, Arnaud … : 25.2 (5.7) Case patients: 62.0 Control participants: 66.0 NR No McParland et al, 1990

273. Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/e6_WqcwDGhgT6bQfmk3Hqj
     February 02, 2021 - These studies included participants with cardiovascular disease risk factors such as diabetes, hypertension … For example, 1 study enrolled participants with no transient ischemic attack or stroke attributable to … the ipsilateral artery for the past 6 months, while another enrolled participants with no history of … A meta-analysis of 3 trials (n = 5223) found that 1.9% (95% CI, 1.2%-2.6%) more participants treated … The studies included in the review included participants with these risk factors, and the USPSTF found

274. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/zHvENvrSUeZh6gFPUK_37c
     February 13, 2018 - women aged 50 to 74 years not known to be at high risk for ovarian cancer.15 More than 95% of trial participants … Eligible participants were women aged 55 to 74 years with- out a previous diagnosis of lung, colorectal … Nearly 90% of participants were white. … in the UK Pilot CA-125 group, 0.97% of participants in the UKCTOCS CA-125 ROCA group, 3.25% of participants … in the UKCTOCS ultrasound group, and 3.17% of participants in the PLCO CA-125 plus ultrasound group.3

275. Archived: Latent Tuberculosis Infection: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/latent-tuberculosis-infection-screening-september-2016
     September 06, 2016 - The trial, published in 1982, included 27,830 participants and evaluated treatment with daily isoniazid … The trial reported fewer deaths attributable to tuberculosis among participants receiving treatment with … The IUAT trial also reported more deaths from hepatotoxicity among participants being treated with isoniazid … There also was a nonsignificant reduced RR of death from hepatotoxicity among participants being treated … Compared with placebo, participants treated with isoniazid had a higher risk of medication discontinuation

276. Evidence Summary: Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/vitamin-supplementation-to-prevent-cvd-and-cancer-preventive-medication
     June 21, 2022 - An estimated 65.1% of all participants were women. … 19.6% of participants were Black, among studies reporting race and ethnicity. … The vitamin D trials had, on average, greater representation of Black participants. … The largest trial, COSMOS, reported that 3.4% of participants taking a multivitamin had died after a … The mean age was 66 years, and an estimated 75% of participants in all trials were women.

277. Draft Recommendation: Screening for Hearing Loss in Older Adults | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/hearing-loss-in-older-adults-screening1
     September 08, 2020 - devices. 18 In one large study of veterans eligible to receive free hearing aids, only 10% of all participants … Among the studies that reported age, the median age of study participants was 69 years. 6 Few studies … provided racial, ethnic, or socioeconomic data on participants. … Included participants were predominantly male (94%), age 50 years or older (mean, 61 years), and recruited … Hearing aid use was very low among participants without baseline perceived hearing impairment (0% to

278. Final Research Plan: Folic Acid for the Prevention of Neural Tube Defects: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan108/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
     October 16, 2014 - registry data) Commentaries, editorials, case reports Sample size More than 50 participants … 50 participants or less Quality Good and fair quality Poor quality

279. Archived: Final Research Plan: Folic Acid for the Prevention of Neural Tube Defects: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan108/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication-january-2017
     October 16, 2014 - registry data) Commentaries, editorials, case reports Sample size More than 50 participants … 50 participants or less Quality Good and fair quality Poor quality

280. Archived: Exercise Tolerance Testing to Screen for Coronary Heart Disease: A Systematic Review: Coronary Heart Disease (Electrocardiography): Screening (2004) | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/exercise-tolerance-testing-to-screen-for-coronary-heart-dise/coronary-heart-disease-electrocardiography-screening-2004
     February 03, 2004 - Among participants with an abnormal baseline result on exercise tolerance testing, those who received … is not clear from the report of this post-hoc analysis whether the cardiovascular risk profiles of participants … To be eligible, studies had to have been performed in participants with no history of cardiovascular … The yield of exercise tolerance testing screening was determined by dividing the number of participants … Mora and colleagues 42 analyzed data from the female participants in the Lipid Research Clinics Prevalence